DTX301

1 stories · following the connections

Business

Ultragenyx Announces Completion of Patient Dosing in First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency

By Nasdaq OMXNov 16, 2017, 1:30 PM UTC